Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

May 2016

New Medical Policy on Treatment of Benign Prostatic Hypertrophy


Harvard Pilgrim has developed a clinical medical policy on the treatment of benign prostatic hypertrophy, which is a non-cancerous inflammation of the prostate. This policy is effective for dates of service on or after August 1, 2016, and was developed to provide greater clarity on the medical necessity of certain treatments.

Harvard Pilgrim considers the following procedures for the treatment of benign prostatic hypertrophy medically necessary and will continue to cover them:

  • Transurethral resection of the prostate (TURP)
  • Transurethral incision of the prostate (TUIP)
  • Transurethral vaporization of the prostate (TUVP)
  • Transurethral enucleation of the prostate (TUEP)
  • Transurethral microwave thermotherapy (TUMT)
  • Transurethral needle ablation (TUNA), also known as transurethral radiofrequency needle ablation (RFNA)
  • Laser prostatectomy and laser-based procedures including contact laser ablation of the prostate (CLAP), holmium laser procedures of the prostate (HoLAP, HoLEP, HoLRP), photoselective laser vaporization (PVP), transurethral ultrasound-guided laser induced prostatectomy (TULIP), and visually guided laser ablation of the prostate (VLAP)
  • Water-induced thermotherapy (WIT)

Harvard Pilgrim considers the following procedures (CPT codes 52441, 52442, and 53855) for the treatment of benign prostatic hypertrophy experimental and investigational and will no longer provide coverage for them:

  • Transprostatic implants (e.g., Urolift System)
  • Insertion of temporary prostatic urethral stent (UroLume)
  • Plasma kinetic vaporization

For further information, please refer to the Benign Prostatic Hypertrophy Medical Policy on our provider website and the Non-Covered Services Payment Policy in our online Provider Manual.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

CLINICIAN CORNER

Coverage of Narcan Nasal Spray and Evzio

Vraylar: New Clinical Requirements for Coverage

Prior Authorization Required for Taltz

New Medical Policy on Treatment of Benign Prostatic Hypertrophy

Identifying and Treating Obsessive-Compulsive Disorder

OFFICE ASSISTANT

Home Care Seasonal Flu Vaccine Fee Schedule Updated for 2016

Reminder: Keep Panel Status Up to Date

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator